Grifols (GIFLF) Total Debt Growth (3y) (2013 - 2025)
Grifols (GIFLF) Total Debt Growth (3y) (2013 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Total Debt Growth (3y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
2.26% |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
31.94% |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
1.29% |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
1.29% |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
16.90% |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
-2.37% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
-4.22% |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
21.55% |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
5.53% |
| 10 |
Grifols |
- |
- |
- |
0.60% |
| Date | Value |
|---|
| Dec 31, 2025 |
0.60% |
| Dec 31, 2024 |
4.31% |
| Dec 31, 2023 |
-50.76% |
| Dec 31, 2022 |
351.91% |
| Dec 31, 2021 |
334.86% |
| Dec 31, 2020 |
6.30% |
| Dec 31, 2019 |
22.25% |
| Sep 30, 2019 |
15.71% |
| Dec 31, 2018 |
-72.68% |
| Sep 30, 2018 |
12.74% |
| Jun 30, 2018 |
3,124.89% |
| Mar 31, 2018 |
17.58% |
| Dec 31, 2017 |
8.66% |
| Dec 31, 2016 |
-74.74% |
| Sep 30, 2016 |
12.99% |
| Jun 30, 2016 |
13.21% |
| Mar 31, 2016 |
-77.38% |
| Dec 31, 2015 |
13.69% |
| Sep 30, 2015 |
13.01% |
| Jun 30, 2015 |
-84.86% |
